<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35811273</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-0502</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis</Title><ISOAbbreviation>Transfus Apher Sci</ISOAbbreviation></Journal><ArticleTitle>Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron.</ArticleTitle><Pagination><StartPage>103499</StartPage><MedlinePgn>103499</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.transci.2022.103499</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1473-0502(22)00180-X</ELocationID><Abstract><AbstractText>Although mass vaccination combined with some other preventative strategies and lockdown was associated with some early signs that COVID-19 infection might be fading away, the over 35 sites mutated new South African variant, "Omicron", emerged almost globally. Certain predisposed hosts may develop severe inflammatory thrombotic or mild long-Covid conditions due to this variant, which depletes T-cells, neutralizes antibodies circulating in the body, and coincidentally induces hypercoagulability. The surge of Omicron combined with Delta variants may confer unresponsiveness to the currently available vaccines even when the second dose is given up to 90 days. A drop in the antibody levels by 30&#xa0;% has been identified in omicron-infected individuals, and one in five people is resistant to antibody treatment. This poses major concerns in the&#xa0;transmissibility rate of this new variant, even in a heavy mass vaccinated environment. This heavily mutated Omicron with other spike sites facilitates viral entry into the cells through conformational changes, irrespective of circulating neutralising antibody. Based on this consideration, we believe that speeding up mixed-matched vaccines with higher T-cell stimulation ability may improve the current situation. Moreover, large orders for antiviral drugs and monoclonal antibodies that could tackle Omicron combined with other variants may be valuable. The use of free polyclonal antibody donations and, hopefully, T-cell immunotherapy, may represent further breakthrough therapeutic interventions. However, Omicron infection is relatively milder than the ongoing Delta variant but is extremely contagious, and therefore the development of novel interventions is highly demanding.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seghatchian</LastName><ForeName>Jerard</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>International Consultancy in Innovative Manufacturing and Quality/Safety of Blood-Derived Bioproducts. London, England, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Paulo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Portuguese Institute of Blood and Transplantation, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanza</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hematology Unit &amp; Romagna Transplant Network, Ravenna, Italy. Electronic address: francesco.lanza@auslromagna.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Transfus Apher Sci</MedlineTA><NlmUniqueID>101095653</NlmUniqueID><ISSNLinking>1473-0502</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hosts' response</Keyword><Keyword MajorTopicYN="N">Monoclonal antibodies therapy</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">Preventive strategies</Keyword><Keyword MajorTopicYN="N">Spike mutation</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>10</Day><Hour>22</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35811273</ArticleId><ArticleId IdType="pmc">PMC9250817</ArticleId><ArticleId IdType="doi">10.1016/j.transci.2022.103499</ArticleId><ArticleId IdType="pii">S1473-0502(22)00180-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Seghatchian J., Lanza F. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: a rousing message of clinical benefit to both donors and recipients alike. Transfus Apher Sci. 2020;59(3) doi: 10.1016/j.transci.2020.102794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2020.102794</ArticleId><ArticleId IdType="pmc">PMC7177094</ArticleId><ArticleId IdType="pubmed">32448638</ArticleId></ArticleIdList></Reference><Reference><Citation>Seghatchian J., Acker J., Putter J. Update on newer approaches to prevent or treat COVID-19 infection: What we all need the most right now!! TransfusApher Sci. 2020;59(5) doi: 10.1016/j.transci.2020.102933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2020.102933</ArticleId><ArticleId IdType="pmc">PMC7470817</ArticleId><ArticleId IdType="pubmed">32919879</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanza F., Agostini V., Monaco F., Passamonti F., Seghatchian J. Therapeutic use of convalescent plasma in COVID-19 infected patients with concomitant hematological disorders. Clin Hematol Int. 2021;3(3):77&#x2013;82. doi: 10.2991/chi.k.210403.001. 16.</Citation><ArticleIdList><ArticleId IdType="doi">10.2991/chi.k.210403.001</ArticleId><ArticleId IdType="pmc">PMC8486975</ArticleId><ArticleId IdType="pubmed">34820612</ArticleId></ArticleIdList></Reference><Reference><Citation>Brissot E., Labopin M., Baron F., Bazarbachi A., Bug G., et al. Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2020;11:1&#x2013;4. doi: 10.1038/s41409-020-0970-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-020-0970-x</ArticleId><ArticleId IdType="pmc">PMC7289070</ArticleId><ArticleId IdType="pubmed">32528122</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoletti A., Tan A.T., Le Bert N. The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. Oxf Open Immunol. 2021;2(1):2021. doi: 10.1093/oxfimm/iqab006. iqab006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfimm/iqab006</ArticleId><ArticleId IdType="pmc">PMC7928654</ArticleId><ArticleId IdType="pubmed">38626271</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan S.C., Shin B.H., Gadsden T.A.M., Chu M., Petrosyan A., Le C.N., et al. T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals. Cell Mol Immunol. 2021:182554&#x2013;182556. doi: 10.1038/s41423-021-00767-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00767-9</ArticleId><ArticleId IdType="pmc">PMC8443898</ArticleId><ArticleId IdType="pubmed">34531555</ArticleId></ArticleIdList></Reference><Reference><Citation>Seghatchian J. Passive immunotherapy using approved vaccines combined with lockdown, as essential parts of the community medicine and public health to survive and even beat COVID: a viewpoint commentary. Arch Community Med Public Health. 2021;7(2):074&#x2013;075. doi: 10.17352/2455-5479.000142.</Citation><ArticleIdList><ArticleId IdType="doi">10.17352/2455-5479.000142</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Tracking SARS-CoV-2 variants, &#x3008;https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/&#x3009;; 2021.</Citation></Reference><Reference><Citation>Seghatchian J. Spotlight on the latest trends on CoV-2 Alpha and Delta variants in the UK; Targeting blood donor population for assessing the effect of the mRNA vaccines on the seroprevalence of CoV-2 Delta variant antibodies and reflections on the management of alloimmunisation in transfused patients with constitutional anaemias in Norway. TransfusApher Sci. 2021;60(5) doi: 10.1016/j.transci.2021.103255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2021.103255</ArticleId><ArticleId IdType="pubmed">34483033</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. COVID vaccine boosters: the most important questions, &#x3008;https://www.nature.com/articles/d41586&#x2013;021-02158&#x2013;6&#x3009;; 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">34354274</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibinga S., Louw V.J., Nedelcu E., Al-Riyami A.Z., Bakhtary S., Johnson S.T., et al. Modeling global transfusion medicine education. Transfusion. 2021;31(10):3040&#x2013;3049. doi: 10.1111/trf.16641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16641</ArticleId><ArticleId IdType="pmc">PMC10936958</ArticleId><ArticleId IdType="pubmed">34469008</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Zhou Y., Ma J., Xia P., Qin Y., Li X. Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients. Ren Fail. 2020;42(1):483&#x2013;488. doi: 10.1080/0886022X.2020.1764369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022X.2020.1764369</ArticleId><ArticleId IdType="pmc">PMC7946020</ArticleId><ArticleId IdType="pubmed">32438839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy M., Michaux I., Lessire S., Douxfils J., Dogn&#xe9; J.M., Bareille M., et al. Prothrombotic hemostasis disturbances in patients with severe COVID-19: a prospective longitudinal observational cohort study. Thromb Res. 2021;197:20&#x2013;23. doi: 10.1016/j.thromres.2020.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.10.025</ArticleId><ArticleId IdType="pmc">PMC7585359</ArticleId><ArticleId IdType="pubmed">33161283</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS. COVID treatment developed in the NHS saves a million lives, &#x3008;https://www.england.nhs.uk/2021/03/covid-treatment-developed-in-the-nhs-saves-a-million-lives/&#x3009;; 2021.</Citation></Reference><Reference><Citation>GOV.UK Government launches COVID-19 Antivirals Taskforce to roll out innovative home treatments this autumn, &#x3008;https://www.gov.uk/government/news/government-launches-covid-19-antivirals-taskforce-to-roll-out-innovative-home-treatments-this-autumn&#x3009;; 2021 [accessed December 7 2021].</Citation></Reference><Reference><Citation>D&#x2019;Alessandro A., Tiffany T., Dzieciatkowaska M., Hill R.C., Richard F., Hudson K.E., et al. Serum proteomics in COVID-19 patients: altered coagulation and complement status as a function of IL-6 level. J Proteome. 2020;19(11):4417&#x2013;4427. doi: 10.1021/acs.jproteome.0c00365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.0c00365</ArticleId><ArticleId IdType="pmc">PMC7640953</ArticleId><ArticleId IdType="pubmed">32786691</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors J.M., Levy J.H. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18(7):1559&#x2013;1561. doi: 10.1111/jth.14849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14849</ArticleId><ArticleId IdType="pmc">PMC9770920</ArticleId><ArticleId IdType="pubmed">32302453</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Zhou T., Zhang Y., Yang E.S., Schramm L., Shi W., et al. Ultra potent antibodies against diverse and highly transmissible CoV-2 variants. Science. 2021;373(6556) doi: 10.1126/science.abh1766. eabh1766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh1766</ArticleId><ArticleId IdType="pmc">PMC9269068</ArticleId><ArticleId IdType="pubmed">34210892</ArticleId></ArticleIdList></Reference><Reference><Citation>Picchianti Diamanti A., Rosado M.M., Pioli C., Sesti G., Lagan&#xe0; B. Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern: the fragile balance between infections and autoimmunity. Int J Mol Sci. 2020;21(9):3330. doi: 10.3390/ijms21093330.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21093330</ArticleId><ArticleId IdType="pmc">PMC7247555</ArticleId><ArticleId IdType="pubmed">32397174</ArticleId></ArticleIdList></Reference><Reference><Citation>Kustin T., Harel N., Finkel U., Perchik S., Harari A., Tahor M., et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021;27:1379&#x2013;1384. doi: 10.1038/s41591-021-01413-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01413-7</ArticleId><ArticleId IdType="pmc">PMC8363499</ArticleId><ArticleId IdType="pubmed">34127854</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangaev A., Ketelaars S.L.C., Isaeva O.I., Patiwael S., Doppler A., et al. Identification and characterisation of a SARS-CoV-2 specific CD8+ T-cell response with immunodominant features. Nat Commun. 2021;12:2593. doi: 10.1038/s41467-021-22811-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22811-y</ArticleId><ArticleId IdType="pmc">PMC8110804</ArticleId><ArticleId IdType="pubmed">33972535</ArticleId></ArticleIdList></Reference><Reference><Citation>Patell R., Bogue T., Koshy A., Aird W.C., et al. Post discharge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020;136(11):1342&#x2013;1346. doi: 10.1182/blood.2020007938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020007938</ArticleId><ArticleId IdType="pmc">PMC7483433</ArticleId><ArticleId IdType="pubmed">32766883</ArticleId></ArticleIdList></Reference><Reference><Citation>Putter J.S., Seghatchian J. An update on COVID-19 infection control measures, plasma-based therapeutics, corticosteroid pharmacotherapy and vaccine research. Transfus Apher Sci. 2020;59(5) doi: 10.1016/j.transci.2020.102934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2020.102934</ArticleId><ArticleId IdType="pmc">PMC7471798</ArticleId><ArticleId IdType="pubmed">32948465</ArticleId></ArticleIdList></Reference><Reference><Citation>Seghatchian J. Editorial: An introductory commentary on the use of artificial intelligence, machine learning and TQM, as novel computational tools in big data patterns or procedural analysis, in transfusion medicine. Transfus Apher Sci. 2020;59(6) doi: 10.1016/j.transci.2020.102985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2020.102985</ArticleId><ArticleId IdType="pubmed">33158743</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Mart&#xed;nez A., Mora-Rillo M., Ferreras C., Guerra-Garc&#xed;a P., Pascual-Miguel B., Mestre-Dur&#xe1;n C., et al. Phase I dose-escalation single center clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19. E. Clin Med. 2021;39 doi: 10.1016/j.eclinm.2021.101086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101086</ArticleId><ArticleId IdType="pmc">PMC8361305</ArticleId><ArticleId IdType="pubmed">34405140</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira P. Author-edition,; Lisbon: 2019. Quality control of qualitative tests for medical laboratories.</Citation></Reference><Reference><Citation>Clinical Laboratory Standards Institute. EP12-A2 User protocol for evaluation of qualitative test performance. 2nd ed. Wayne (PA): CLSI.</Citation></Reference><Reference><Citation>Bettencourt da Silva R., Ellison S.L.R. (eds.). Eurachem/CITAC Guide: Assessment of performance and uncertainty in qualitative chemical analysis.1st ed. Eurachem, 2021.</Citation></Reference><Reference><Citation>Putter J.S. Immunotherapy for COVID-19: evolving treatment of viral infection and associated adverse immunological reactions. Transfus Apher Sci. 2021;60(2) doi: 10.1016/j.transci.2021.103093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2021.103093</ArticleId><ArticleId IdType="pmc">PMC7881713</ArticleId><ArticleId IdType="pubmed">33610448</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez E., Haycroft E.R., Adair A., et al. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight. 2021;6(16) doi: 10.1172/jci.insight.150012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.150012</ArticleId><ArticleId IdType="pmc">PMC8409985</ArticleId><ArticleId IdType="pubmed">34251356</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Zhang Y., Li D., Deng Y.Q., Xu H., Zhao C., et al. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Signal Transduct Target Ther. 2021;6(1):389. doi: 10.1038/s41392-021-00797-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00797-9</ArticleId><ArticleId IdType="pmc">PMC8578532</ArticleId><ArticleId IdType="pubmed">34759261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanza F., Seghatchian J. An overview of current position on cell therapy in transfusion science and medicine: from fictional promises to factual and perspectives from red cell substitution to stem cell therapy. TransfusApher Sc. 2020 4 doi: 10.1016/j.transci.2020.102940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2020.102940</ArticleId><ArticleId IdType="pubmed">32950375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanza F., Seghatchian J. Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients. Br J Haematol. 2020 doi: 10.1111/bjh.16814. 10.1111/bjh.16814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16814</ArticleId><ArticleId IdType="pmc">PMC7272917</ArticleId><ArticleId IdType="pubmed">32407543</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>